Lanean...
Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
OBJECTIVE: Bevacizumab is an important component in the treatment of various cancers, and despite guidelines recommending its use in both ovarian and cervical cancer, patient access to bevacizumab and other angiogenesis inhibitors is limited. Biosimilars are large, structurally complex molecules tha...
Gorde:
| Argitaratua izan da: | Gynecol Oncol Res Pract |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5361700/ https://ncbi.nlm.nih.gov/pubmed/28344818 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40661-017-0045-x |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|